Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics (Nasdaq: KPTI) and Menarini Group announced that the European Commission has granted orphan medicinal product designation for selinexor to treat myelofibrosis (MF). This follows the FDA's orphan designation for selinexor in May 2022. Karyopharm is studying selinexor as a monotherapy and in combination with ruxolitinib for MF. Selinexor is a first-in-class XP01 inhibitor. The designation provides financial and regulatory incentives, including 10-year marketing exclusivity in the EU after approval.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2022 financial results on November 3, 2022. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead product, XPOVIO® (selinexor), which is approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets. Investors interested in KPTI should tune in to the call for key financial insights.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced on October 3, 2022, the granting of stock options and restricted stock units (RSUs) to new employees, including Executive VP Lisa DiPaolo. On September 30, 2022, a stock option to purchase 1,200 shares at $5.46 per share was awarded to a new hire, while DiPaolo received options for 100,000 shares and 65,000 RSUs at the same exercise price. The awards vest over four years, linked to ongoing employment. These inducements comply with Nasdaq rules and aim to attract talent essential for the company's innovative cancer therapies.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced participation in two investor conferences this September. The Morgan Stanley 20th Annual Global Healthcare Conference will take place on September 12, 2022, at 12:30 p.m. ET, followed by the Baird 2022 Global Healthcare Conference on September 13, 2022, at 12:50 p.m. ET. Live webcasts and slides will be available on their website for 90 days post-event. Karyopharm specializes in oral cancer treatments, including its lead compound, XPOVIO®.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on Sept. 1, 2022, the approval of stock options for 40,800 shares and 28,000 restricted stock units (RSUs) to eight new employees, aimed at incentivizing key talent. The stock options are priced at $5.06, aligning with the common stock's closing price as of August 31, 2022. Each equity award will vest over four years, contingent on continued employment. Additionally, 7,500 RSUs were granted to Johanna Shulman, VP, Program Lead, with specific vesting terms defined. These grants comply with Nasdaq Listing Rule 5635(c)(4).
Karyopharm Therapeutics (KPTI) reported impressive Q2 2022 results with total revenue of $39.7 million, a 76% increase year-over-year. Net product revenue from XPOVIO® reached $29.0 million, up 44% from Q2 2021. Full marketing authorization for NEXPOVIO® was granted by the European Commission for adults with multiple myeloma who had prior therapy. The company updated its 2022 revenue guidance to between $155 million and $165 million. Despite challenges due to COVID-19 and competition, Karyopharm expects to maintain a cash runway into early 2024.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the 2022 Wedbush Pacgrow Healthcare Conference. The virtual event will feature a fireside chat with the company's senior management team on August 9, 2022, at 4:05 p.m. ET. Investors can access the live webcast on Karyopharm's website under the 'Events & Presentations' section, which will be available for replay for 90 days post-event. Karyopharm is known for pioneering novel cancer therapies and its lead compound, XPOVIO (selinexor), is approved in multiple oncology indications.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options for 26,100 shares and 18,000 restricted stock units (RSUs) to eight new employees, effective July 29, 2022. The stock options have an exercise price of $4.25 and will vest over four years. RSUs will similarly vest over four years, contingent upon the employees’ continued service. This grant is part of Karyopharm's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). Karyopharm focuses on innovative cancer therapies, including its leading product, XPOVIO®.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) will announce its second quarter 2022 financial results on August 4, 2022, at 8:00 a.m. ET. The management team will host a conference call to discuss these results and provide updates on the company. Karyopharm is recognized for its novel cancer therapies, particularly its oral Exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), which has regulatory approvals in various regions. For further details, visit their investor website.
Karyopharm Therapeutics Inc. (KPTI) and the Menarini Group announced the European Commission's full approval for NEXPOVIO® (selinexor) for treating adults with multiple myeloma after at least one prior therapy. This follows a positive opinion from the CHMP in May 2022 and is based on the Phase 3 BOSTON study results, which showed improved patient outcomes. The approval allows for extended use in all EU member states and select countries, addressing a significant medical need as approximately 51,000 new multiple myeloma cases arise annually in Europe.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
